Drug intelligence / Profile preview

LYB002CA

Development stage: Unknown
Lead developer: Guangzhou Patronus Biotech
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

LYB002CA is a recombinant SARS-CoV-2 trivalent vaccine (CHO Cell) developed as a booster for individuals who have previously received a three-dose primary series of inactivated COVID-19 vaccines. It is administered via intramuscular injection and has been evaluated for safety and immunogenicity in healthy adults aged 18–59 years. The vaccine aims to enhance immune response by increasing S-protein binding antibody IgG concentrations following initial vaccination with inactivated COVID-19 vaccines.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on LYB002CA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LYB002CA.

Explore the full profile